Tower Research Capital LLC TRC Raises Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Tower Research Capital LLC TRC boosted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 413.2% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 20,898 shares of the company's stock after buying an additional 16,826 shares during the period. Tower Research Capital LLC TRC's holdings in Takeda Pharmaceutical were worth $277,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TAK. Summit Global Investments lifted its holdings in shares of Takeda Pharmaceutical by 75.5% in the 4th quarter. Summit Global Investments now owns 729,200 shares of the company's stock worth $9,655,000 after acquiring an additional 313,642 shares during the last quarter. Crossmark Global Holdings Inc. lifted its stake in Takeda Pharmaceutical by 284.9% in the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company's stock worth $2,787,000 after purchasing an additional 155,795 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at approximately $1,447,000. Marshall Wace LLP bought a new stake in shares of Takeda Pharmaceutical during the 4th quarter worth approximately $1,010,000. Finally, Boston Partners purchased a new position in Takeda Pharmaceutical during the 4th quarter valued at $915,000. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Trading Down 1.2 %

Shares of Takeda Pharmaceutical stock traded down $0.18 on Tuesday, hitting $15.20. 2,297,882 shares of the company traded hands, compared to its average volume of 1,873,865. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The stock's 50 day moving average price is $14.86 and its 200-day moving average price is $13.98. The company has a market cap of $48.36 billion, a PE ratio of 38.00, a PEG ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a 52 week low of $12.58 and a 52 week high of $15.43.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.